Purpose: We present the multifocal electroretinogram (mfERG) with a 7-hexagon array as an objective test of macular function that can be recorded in 14 s. We provide normal values and investigate its reproducibility and validity. Methods: Healthy participants underwent mfERG testing according to International Society for Clinical Electrophysiology of Vision (ISCEV) standards using the Espion Profile/D310 multifocal ERG system (Diagnosys, LLC, Lowell, MA, USA). One standard recording of a 61-hexagon array and 2 repeated recordings of a custom 7-hexagon array were obtained. Results: A total of 13 subjects (mean age 46.9 years) were included. The median response densities were 12.5 nV/deg2 in the center and 5.2 nV/deg2 in the periphery. Intereye correlations were strong in both the center (ρCenter = 0.821; p < 0.0001) and the periphery (ρPeriphery = 0.862; p < 0.0001). Intraeye correlations were even stronger: ρCenter = 0.904 with p < 0.0001 and ρPeriphery = 0.955 with p < 0.0001. Bland-Altman plots demonstrated an acceptable retest mean difference in both the center and periphery, and narrow limits of agreement. We found strong correlations of the center (ρCenter = 0.826; p < 0.0001) and periphery (ρPeriphery = 0.848; p < 0.0001), with recordings obtained by the 61-hexagon method. Conclusions: The 7-hexagon mfERG provides reproducible results in agreement with results obtained according to the ISCEV standard.

Keywords:
Macular degeneration, Retina, Dystrophy, Outcome parameters, Multifocal electroretinogram, Full-field electroretinogram, Reproducibility, Validity
1.
Hood DC, Bach M, Brigell M, et al: ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition). Doc Ophthalmol 2012;124:1-13.
2.
Sutter EE, Tran D: The field topography of ERG components in man. I. The photopic luminance response. Vision Res 1992;32:433-446.
3.
Kong X, Strauss RW, Michaelides M, et al: Visual acuity loss and associated risk factors in the retrospective Progression of Stargardt Disease study (ProgStar report No. 2). Ophthalmology 2016;123:1887-1897.
4.
Schönbach EM: Cross-sectional evaluation of microperimetric fixation location and stability in Stargardt disease in the ProgStar study (abstract 2694). Annual ARVO Meeting, Seattle, May 2016.
5.
Schönbach EM, Ibrahim M, Strauss RW, et al: Fixation location and stability using the MP-1 microperimeter in Stargardt disease: ProgStar report No. 3. Ophthalmol Retina 2017;1:68-76.
6.
Scholl HN, Shah S: We need to be better prepared for hydroxychloroquine retinopathy. JAMA Ophthalmology 2014;132:1460-1461.
7.
Maturi RK, Yu M, Weleber RG: Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol 2004;122:973-981.
8.
Lai TY, Chan WM, Li H, Lai RY, Lam DS: Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol 2005;140:794-807.
9.
Lyons JS, Severns ML: Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol 2007;143:801-809.
10.
Scholl HP, Schuster AM, Vonthein R, Zrenner E: Mapping of retinal function in Best macular dystrophy using multifocal electroretinography. Vision Res 2002;42:1053-1061.
11.
Schonbach EM, Scholl HP: Fundus autofluorescence in a subclinical case of Best disease. Retin Cases Brief Rep 2017;11(suppl 1):S159-S162.
12.
Scholl HP, Besch D, Vonthein R, Weber BH, Apfelstedt-Sylla E: Alterations of slow and fast rod ERG signals in patients with molecularly confirmed Stargardt disease type 1. Invest Ophthalmol Vis Sci 2002;43:1248-1256.
13.
Strauss RW, Ho A, Munoz B, et al: The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: design and baseline characteristics: ProgStar report No. 1. Ophthalmology 2016;123:817-828.
14.
Bellmann C, Neveu MM, Scholl HP, et al: Localized retinal electrophysiological and fundus autofluorescence imaging abnormalities in maternal inherited diabetes and deafness. Invest Ophthalmol Vis Sci 2004;45:2355-2360.
15.
Feucht N, Schonbach EM, Lanzl I, Kotliar K, Lohmann CP, Maier M: Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease. Clin Ophthalmol 2013;7:173-178.
16.
Parisi V, Perillo L, Tedeschi M, et al: Macular function in eyes with early age-related macular degeneration with or without contralateral late age-related macular degeneration. Retina 2007;27:879-890.
17.
Parisi V, Tedeschi M, Gallinaro G, et al: Carotenoids and antioxidants in age-related maculopathy Italian study: multifocal electroretinogram modifications after 1 year. Ophthalmology 2008;115:324-333e2.
18.
Han Y, Bearse MA Jr, Schneck ME, Barez S, Jacobsen CH, Adams AJ: Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Vis Sci 2004;45:948-954.
19.
Meigen T, Friedrich A: The reproducibility of multifocal ERG recordings. Ophthalmologe 2002;99:713-718.
20.
Parks S, Keating D, Williamson TH, Evans AL, Elliott AT, Jay JL: Functional imaging of the retina using the multifocal electroretinograph: a control study. Br J Ophthalmol 1996;80:831-834.
21.
Yoshii M, Yanashima K, Wakaguri T, et al: A basic investigation of multifocal electroretinogram: reproducibility and effect of luminance. Jpn J Ophthalmol 2000;44:122-127.
22.
Bultmann S, Rohrschneider K: Reproducibility of multifocal ERG using the scanning laser ophthalmoscope. Graefes Arch Clin Exp Ophthalmol 2002;240:841-845.
23.
Hebert M, Lachapelle P, Dumont M: Reproducibility of electroretinograms recorded with DTL electrodes. Doc Ophthalmol 1995;91:333-342.
24.
Hebert M, Vaegan, Lachapelle P: Reproducibility of ERG responses obtained with the DTL electrode. Vision Res 1999;39:1069-1070.
25.
Schönbach EM, Wolfson Y, Strauss RW, et al; ProgStar Study Group: Macular sensitivity measured with microperimetry in Stargardt disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) study: report No. 7. JAMA Ophthalmol DOI: 10.1001/jamaophthalmol.2017.1162.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.